company background image
CAPR

Capricor Therapeutics NasdaqCM:CAPR Stock Report

Last Price

US$4.89

Market Cap

US$119.1m

7D

7.9%

1Y

21.6%

Updated

15 Aug, 2022

Data

Company Financials +
CAPR fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

CAPR Stock Overview

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders.

Capricor Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Capricor Therapeutics
Historical stock prices
Current Share PriceUS$4.89
52 Week HighUS$5.85
52 Week LowUS$2.56
Beta5.03
1 Month Change-3.17%
3 Month Change55.24%
1 Year Change21.64%
3 Year Change63.54%
5 Year Change-52.52%
Change since IPO-88.36%

Recent News & Updates

Aug 10

Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03

Capricor Therapeutics press release (NASDAQ:CAPR): Q2 GAAP EPS of -$0.29 misses by $0.03. As of June 30, 2022, the Company’s cash, cash equivalents and marketable securities totaled approximately $51.4 million, compared to approximately $34.9 million on December 31, 2021. No shares were sold under the Company’s at-the-market program in the second quarter of 2022. Shares -2.65%.

Shareholder Returns

CAPRUS BiotechsUS Market
7D7.9%1.4%3.6%
1Y21.6%-19.6%-9.6%

Return vs Industry: CAPR exceeded the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: CAPR exceeded the US Market which returned -10.2% over the past year.

Price Volatility

Is CAPR's price volatile compared to industry and market?
CAPR volatility
CAPR Average Weekly Movement11.2%
Biotechs Industry Average Movement12.6%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: CAPR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: CAPR's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200548Linda Marbánhttps://www.capricor.com

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19.

Capricor Therapeutics, Inc. Fundamentals Summary

How do Capricor Therapeutics's earnings and revenue compare to its market cap?
CAPR fundamental statistics
Market CapUS$119.05m
Earnings (TTM)-US$25.05m
Revenue (TTM)n/a

0.0x

P/S Ratio

-4.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CAPR income statement (TTM)
RevenueUS$0
Cost of RevenueUS$16.61m
Gross Profit-US$16.61m
Other ExpensesUS$8.44m
Earnings-US$25.05m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.03
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did CAPR perform over the long term?

See historical performance and comparison